{"title":"拉帕替尼联合曲妥珠单抗治疗人表皮生长因子受体2阳性转移性乳腺癌的II期研究:早期氟脱氧葡萄糖正电子发射断层成像(TBCRC 003)的临床结果和预测价值","authors":"A.B. Tabchy MD, MS","doi":"10.1016/j.breastdis.2016.04.014","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":9266,"journal":{"name":"Breast Diseases: A Year Book Quarterly","volume":"27 2","pages":"Pages 125-126"},"PeriodicalIF":0.0000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.breastdis.2016.04.014","citationCount":"0","resultStr":"{\"title\":\"Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003)\",\"authors\":\"A.B. Tabchy MD, MS\",\"doi\":\"10.1016/j.breastdis.2016.04.014\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":9266,\"journal\":{\"name\":\"Breast Diseases: A Year Book Quarterly\",\"volume\":\"27 2\",\"pages\":\"Pages 125-126\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.breastdis.2016.04.014\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast Diseases: A Year Book Quarterly\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1043321X16300169\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Diseases: A Year Book Quarterly","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1043321X16300169","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003)